MedTech Resources

FDA Clearance Tracker

Methods & limitations

Where the numbers come from, how we count them, and what this tool cannot tell you.

Last checked: Nov 19, 2026Source: openFDA

Where the data comes from

Every decision comes from openFDA, the public data service FDA runs for its own device databases. We use two of its datasets: 510(k) (which also holds De Novo grants) and PMA. We do not edit the records. Company names, device names and dates appear as FDA recorded them.

  • The tool covers decisions dated January 1, 2015 or later. Older decisions exist in FDA's databases but are left out here.
  • FDA usually posts a decision about a week after it is made, and openFDA refreshes about once a week. The newest few days are always missing.
  • We ask openFDA again at most every 6 hours, so this tool can lag FDA's own database by up to a day beyond that.
  • Each page shows a "Last checked" date and the date of the newest record, so you can see how fresh the view is.

What the three pathways mean

  • 510(k) clearance. FDA found the device substantially equivalent to a device already on the market. Most devices reach the market this way. It is a clearance, not an approval.
  • De Novo grant. FDA created a new device type for a low to moderate risk device with nothing to compare it to.
  • PMA approval. The pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness.

A clearance, grant or approval is a regulatory decision. It does not tell you whether a device will be reimbursed, adopted by physicians or commercially successful, and it is not a recommendation of any company or security.

PMA supplements

An approved PMA device collects supplements for the rest of its life: manufacturing changes, labeling changes, new sites. There are thousands a year and most say little about new technology.

  • By default the tool shows original PMA approvals and panel-track supplements. A panel-track supplement is a significant change, such as a new indication, that needed clinical data.
  • Tick "Include every PMA supplement" in the filters to see all of them.
  • Counts and charts always use the default (originals and panel-track supplements), whatever the filter says.

De Novo limitations

  • FDA's data does not assign a De Novo grant to an advisory committee the way it does a 510(k). We place each grant in a specialty using the committee that reviewed it and its product code. A grant whose record names no reviewing committee appears only in unfiltered views.
  • The "Most active specialties" count on the landing page leaves De Novo grants out for the same reason. The yearly trend table includes them.
  • A new product code is created with each grant, so FDA's name for the device type can be missing for the first weeks.
  • Decision summaries are posted some time after the grant. A link to a recent one may not open yet.

Breakthrough Devices limitations

The "Breakthrough" flag means one thing only: the decision number appears on FDA's public list of Breakthrough Devices with marketing authorization. Our copy of the list is dated June 30, 2026 and has 206 devices.

  • FDA does not publish which devices hold the designation before they are authorized. Hundreds of designated devices are not on the list because they have not reached the market.
  • FDA updates the list a few times a year. A device authorized after June 30, 2026 will not be flagged until we load the next list, even if it is a Breakthrough Device.
  • The absence of the flag is not evidence that a device lacks the designation.
  • We do not use company press releases or any other source for this flag.

"New device type" and "First of its product code"

  • New device type is shown on every De Novo grant. That is what a De Novo grant is.
  • First of its product code is shown when a decision is the earliest one in FDA's 510(k) and PMA data under its product code. This check looks at all years, not only 2015 onward.
  • FDA sometimes splits, merges or renames product codes. A device can be first under a new code while similar devices exist under an older one.
  • In lists, we run the check on at most six product codes per page, so a first-of-code decision can occasionally go unflagged in a list. Its own page always runs the check.
  • Neither flag is a judgment that a device is better, safer or more valuable than others.

Time to decision

We count calendar days from the date FDA received the submission to the date it decided. FDA's own performance figures count "FDA days", which stop the clock while FDA waits for the applicant to answer questions. Our numbers are longer than those and are not comparable to them.

  • 510(k) medians use the 1,000 most recent clearances. De Novo uses the 150 most recent grants and PMA the 200 most recent original approvals, which reach back further in time.
  • A specialty needs at least 15 clearances in the sample to be listed.
  • The figures describe past decisions. They are not a forecast for any pending submission.
  • Trend figures are rebuilt once a day.

Specialties, companies and searching

  • Specialties follow FDA's review panels (for example Cardiovascular or Orthopedic). Sub-specialties such as electrophysiology are our own groupings of product codes and will miss some devices.
  • Company search matches the applicant name as FDA recorded it. Subsidiaries, former names and spelling variants are separate. The applicant is the company that filed, which is not always the brand owner.
  • With no pathway chosen, the list merges two FDA datasets and stops after 150 decisions. Pick a pathway or a date range to go further back.
  • If openFDA does not answer, the page says so and shows what it has. It does not show stale numbers as if they were current.

What is not here yet

  • Predicate devices. They are named in each 510(k) summary document, which we link to but do not read yet.
  • Devices that are exempt from premarket review, and devices authorized under emergency use.
  • Drugs and biologics. This tool covers devices only.

Back to the FDA Clearance Tracker

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.